Classical Hodgkin lymhpoma (BSH 2013, 2014 & 2022)

CD30+, CD15+

CD45-, CD20-, CD3-

 

epidemiology

 

Annual Incidence 2.7 / 100,000 in UK

Two peaks at 20-34 and >70

 

Initial Work-up


Bloods - FBC, ESR, U&E, LFT, Bone profile, HIV, hep B/C

Biopsy - 4 histological subtypes - Nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte-depleted - but no difference in outcomes

PET-CT - For staging. Detects bone involvement. BM biopsy not required.

Fertility preservation - consider prior to treatment


Staging

 

Early (Stage I/II)

  • Favourable (GHSG) requires:

    • No large mediastinal mass

    • ESR <50 without B symptoms or ESR <30 with B symptoms

    • No extranodal disease

    • 1-2 lymph nodes involved (BSH guideline has LN chart)

  • Favourable (EORTC) requires:

    • No large mediastinal mass

    • ESR <50 without B symptoms or ESR <30 with B symptoms

    • Age 50 years or younger

    • 1-3 lymph nodes involved (BSH guideline has LN chart)

  • Unfavourable – Not meeting the favourable criteria

 

N.B. Large mediastinal mass = mediastinal thoracic ratio >0.33 (UK NCRI / GHSG) or >0.35 (EORTC)

Advanced (Stage III/IV)

 

Prognostic Scores


Advanced stage patients should have Hasenclever/IPS calculated.

Hogkin IPS, one point for each of:

  • Serum albumin <40g/l

  • Hb <105g/l

  • Male sex

  • Ann Arbor Stage IV

  • Age 45 years or greater

  • WBC 15x10e9/l or above

  • Lymphocyte count 0.6x10e9/l or below

Hodgkin IPS 5-yr OS, by No. of risk factors

  • 0 - 89%

  • 1 - 90%

  • 2 - 81%

  • 3 - 78%

  • 4 - 61%

  • 5 or more - 56%


first line treatment

 

ABVD – Doxorubicin, Bleomycin, Vinblastine, Dacarbazine

escBEACOPP – Bleomycin, Etoposide,Doxorubicin, Cyclophosphamide,Vincristine, Pred, Procarbazine

escBEACOPDac - Dacarbazine instead of procarbazine —> reduced gonadal toxicity and neutropenia in paediatric randomised trials. In adult audit, reduced RBC transfusion and hospital admissions.


PET negative in Hodgkin = Deauville score 1-3


Early Stage, Favourable

  • ABVD x2 —> PET-CT

    • iPET2 negative —> options: AVDx1 + RT or AVDx2 with no RT (selected pts)

    • iPET2 positive —> EscBEACOPP x2 + 20Gy RT

 

Early Stage, Unfavourable / Intermediate

  • ABVD x2 —> PET-CT

    • iPET2 negative —> options: AVD x4 or AVD x2 + 30Gy RT

    • iPET2 positive —> EscBEACOPP x2 + RT

  • (HD14+17) EscBEACOPP x2 + ABVD x2 (“2+2”) —> PET-CT

    • iPET2 negative —> Stop

    • iPET2 positive —> 30Gy RT


Advanced Disease, Age <60

  • (RATHL) ABVD x2 —> PET-CT

    • iPET2 negative —> AVD x4

    • iPET2 positive —> escBEACOPP x4 +/- RT

  • (HD18) escBEACOPP x2 —> PET-CT

    • iPET2 negative —> escBEACOPP x2 or AVD x4

    • iPET2 positive —> escBEACOPP x4 +/- RT


Some amalgamated ABVD / escBEACOPP stats:

  • ABVD                       PFS 73%,        OS 82-90%    Fertility >30 y.o. 94%

  • escBEACOPP          PFS 89%,        OS 95%          Fertility >30 y.o. 45%

  • 2/3 of BEACOPP patients have grade 3-4 infections and increased hospital admissions


Supportive Care

  • Life-long irradiated blood products

  • GCSF not required for ABVD, do not delay for neutropenia

  • GCSF for escBEACOPP / BV-AVD

  • Aciclovir + Co-trimoxazole prophylaxis for escBEACOPP


HIV-related Hodgkins

  • ABVD + Anti-retroviral therapy

  • No data for BEACOPP


Teenage and Young Adults (TYA)

  • Paediatric or adult regimens can be considered

  • Late toxicities particularly important consideration

  • Don’t forget fertility preservation 


Pregnancy

  • Delaying chemotherapy until after delivery is not standard practice

  • Consider alternative imaging – USS / MRI

  • ABVD can be used in all 3 trimesters based on retrospective data, prefer to avoid in 1st

  • Excellent outcomes reported

 

Age >60 yo

  • 20% of Hodgkin Lymphoma patients

  • ABVD - excellent response rates but 5% TRM (HD10 and HD11)

  • BEACOPP - 21% TRM in HD9 trial – avoid

  • Use standardized frailty assessment tool

  • Consider limiting number of cycles

  • ‘Frail’ patients - avoid anthracyclines, e.g. conside ChlVPP

 

1st Line Treatment Summary

 

Relapse / Refractory treatment

 

1o Resistant = Progression or non-response during induction treatment or within 90 days of completion

Relapse = Occurring >90 days from completion of induction treatment (early <12 mo, late >12 mo)

 

Poor outcomes

  • Resistant worse than relapse

  • Limited prognostic models – PET-CT probably the most informative

  • Salvage followed by Autograft if fit patients (about 1/3 of patients make it to transplant)

 

Palliative regimens

  • Single agent – vinblastine, etoposide, gemcitabine

  • Multi-agent – PECC, ChlVPP

 

Novel Therapies

  • Brentuximab – Anti-CD30 + Anti-microtubulin agent.

    • Current NICE approval for relapse after 2 prior therapies or relapse after autograft (as of April 2019)

  • Pembrolizumab & Nivolumab – Anti-programmed death 1 (PD-1) pathway antibodies

    • Pembrolizumab - via cancer drugs fund

    • Nivolumab - Current NICE approval for relapse post autograft + brentuximab (as of April 2019)

  • Avelumab - Anti-programmed death ligand 1 (PD-L1) antibody

 

Long-term Follow-Up

 

Minimum 2 years clinic follow-up from 1st line treatment

Irradiated blood products for life

No role for routine radiological surveillance

Lifestyle advice


Late Effects

  • Radiotherapy

    • Breast cancer - breast screening if received RT under age 36

    • Thyroid cancer and hypothyroidism - lifelong increased risk

  • Chemotherapy/Radiotherapy

    • Cardiac disease - lifelong increased risk of MI, valve disease, heart failure

    • Respiratory toxcity - breathlessness, firbosis, pneumonitis

    • Second cancers - e.g. 0.4% MDS/AML post escBEACOPP

    • Reduced fertility (see above)

    • Chronic fatigue

    • Anxiety / depression

  • These late effects have driven the many de-escalation trials mentioned above and highlight need to involve patients in discussions about their priorities / attitudes to risk.

 

Relevant trials


Early Stage, Favourable

Overall: RT improved PFS, but OS gain not yet demonstrated. iPET pos pts had higher relapse risk.

HD16 trial 2019

  • Early stage, favourable only

  • ABVD x2 —> no RT if iPET2 negative (non-inferiorty design)

H10 trial 2017

  • Early stage (subdivided favourable or unfavourable).

  • Experimental arm: ABVD x2 —> no RT if iPET2 negative (non-inferiorty design)

RAPID 2015

  • Early stage, favourable or unfavourable

  • Experimental arm: ABVD x3 —> no RT if iPET2 negative (non-inferiorty design)

Early Stage, Unfavourable / Intermediate

HD17 trial 2021

  • PET-adapted 2+2, confirmed omitting RT if PET negative is non-inferior.

HD14 trial 2012

  • ABVD x4 vs escBEACOPP x2 + ABVD x2 (‘2+2’)

  • All patient also got RT

HD11 trial 2010

  • ABVD x4 vs escBEACOPP x4 and 30Gy vs 20Gy RT

Advanced Disease

US SWOG S0816 2019

  • ABVD x2 —> iPET2 —> Switch to EscBEACOPP if postive

AHL2011 trial 2019

  • EscBEACOPP x2 —> iPET2 —> if neg then ABVD x4.

  • Not so commonly used in UK

ECHELON1 trial 2018

  • ABVD vs BV-AVD (Brentuximab vedotin). (5yr f/up)

HD18 trial 2017

  • EscBEACOPP x2 —> iPET2 —> if neg then x2 vs x4 vs x6 further cycles.

  • Total of 4 cycles is non-inferior and less toxic (+ shorter total treatment length).

UK RATHL 2016

  • ABVD x2 —> iPET2 —> Switch to EscBEACOPP if postive (16% of pts). Established non-inferiority of further AVD x4 vs ABVD x4 with less lung toxicity. IPS 3 & 4 pts higher relapse rates.

HD15 trial 2012:

  • EscBEACOPP x6 vs x8 (non-inferiority design)

HD9 trial 2009

  • Baseline vs escalated dosing of BEACOPP